Recombinant 191-amino-acid growth hormone
Somatropin (HGH 191 AA)
Direct GH- increasing IGF-1, lipolysis, and linear growth programmes depending on developmental context.
Primary Mechanism of Action
Clinical / Scientific
191-AA somatropin binds GH receptors, activating JAK2–STAT5 and related . Hepatic IGF-1 production mediates many anabolic effects; GH also has direct lipolytic and anti- effects in adipose and liver.
Pathway Targets
GH receptor
Scientific explanation
JAK–STAT transcriptional agonism.
IGF-1
Scientific explanation
Downstream endocrine mediator.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GH receptor → IGF-1
Mechanistically Relevant Repurposed & Adjunctive Applications
GH deficiency and labelled paediatric/adult indications
EstablishedMechanistic rationale
Recombinant GH is established for labelled deficiency and selected syndromes. Research vials are not a substitute for licensed somatropin products.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GHR | Agonism | IGF-1 and metabolic gene programs | Established mechanism |
Mechanistic Interaction Considerations
Increases resistance; oedema; theoretically additive with secretagogues. Contraindicated in active malignancy in labelled GH products.
In Plain Language
This is a lab-made full growth-hormone protein (191 amino acids). It tells liver and other tissues to raise IGF-1 and change growth and fat metabolism.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.